{
    "clinical_study": {
        "@rank": "149868", 
        "brief_summary": {
            "textblock": "To demonstrate the safety and tolerability of subcutaneously administered interleukin-2\n      (IL-2) plus antiretrovirals in patients with HIV infection and CD4 counts of 350 cells/mm3\n      or more.  To demonstrate the immunological efficacy of subcutaneous IL-2 therapy plus\n      antiretroviral therapy relative to antiretroviral therapy alone.\n\n      IL-2, given through injection under the skin, in combination with anti-HIV therapy can\n      increase CD4 cell counts.  This study examines 3 doses of IL-2 in order to determine the\n      safest and most effective dose to use."
        }, 
        "brief_title": "A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3", 
        "completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Interleukin-2 administered subcutaneously, in combination with antiretrovirals, results in\n      increases in CD4+ cell count that might impact upon HIV disease progression. A Phase III\n      trial involving large numbers of HIV-positive patients is the next step in the development\n      process. To develop appropriate clinical experience with the combination, this Phase II\n      trial will allow administration of IL-2 plus antiretroviral therapy to a small number of\n      patients in sites being considered for the Phase III trial.\n\n      Patients are randomized to control therapy with antiretrovirals alone (36 patients) or\n      antiretrovirals plus IL-2 given subcutaneously every 12 hours for 5 days every 8 weeks.\n      Three doses of IL-2 are studied, with 12 patients evaluated at each dose.\n\n      If at least 9 of the first 12 patients complete the 5-day dosing period without\n      dose-limiting toxicities, the next 12 patients randomized are treated with the next higher\n      dose; if this dose is tolerated, the last 12 patients randomized receive the highest study\n      dose. Patients enrolled at the first two doses of IL-2 who complete three courses have their\n      dose escalated to a maximum of the highest dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this study if you:\n\n          -  Are HIV-positive.\n\n          -  Have a CD4 cell count greater than or equal to 300 cells/mm3.\n\n          -  Are at least 18.\n\n          -  Have been on antiretroviral therapy for at least 7 days prior to study entry.\n\n        Exclusion Criteria\n\n        You will not be eligible for this study if you:\n\n          -  Abuse alcohol or drugs, or have any serious psychiatric or medical illnesses that\n             would affect your safety or ability to complete the study.\n\n          -  Have a history of cancer (other than Kaposi's sarcoma), an AIDS-defining illness, a\n             central nervous system (CNS) abnormality, or an autoimmune/inflammatory disease.\n\n          -  Are pregnant or breast-feeding.\n\n          -  Have ever received IL-2."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "72", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000889", 
            "org_study_id": "IRP 021A", 
            "secondary_id": [
                "10467", 
                "SQ 1 ARG", 
                "SQIL-2 Argentina"
            ]
        }, 
        "intervention": {
            "intervention_name": "Aldesleukin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Aldesleukin", 
                "Interleukin-2"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Interleukin-2", 
            "CD4 Lymphocyte Count", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "link": {
            "description": "Click here for more information about Aldesleukin", 
            "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=21"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ciudad de Buenos Aires", 
                        "country": "Argentina", 
                        "state": "Buenos Aires"
                    }, 
                    "name": "Hospital de Clinicas 'Jose de San Martin' C601-040 CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ciudad de Buenos Aires", 
                        "country": "Argentina", 
                        "state": "Buenos Aires"
                    }, 
                    "name": "Hospital F.J. Muniz C601-050 CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ciudad de Buenos Aires", 
                        "country": "Argentina", 
                        "state": "Buenos Aires"
                    }, 
                    "name": "Hospital General de Agudos J.M. Ramos Mejia CPCRA CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ciudad de Buenos Aires", 
                        "country": "Argentina", 
                        "state": "Buenos Aires"
                    }, 
                    "name": "Hospital Italiano de Buenos Aires C601-020 CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "Argentina"
        }, 
        "official_title": "A Randomized, Open-Label, Phase II Study of Subcutaneous Interleukin-2 (Proleukin) Plus Antiretroviral Therapy vs. Antiretroviral Therapy Alone in Patients With HIV Infection and at Least 350 CD4+ Cells/mm3", 
        "overall_official": {
            "last_name": "M Losso", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000889"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 1997", 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }, 
    "geocoordinates": {
        "Hospital F.J. Muniz C601-050 CRS": "-34.608 -58.373", 
        "Hospital General de Agudos J.M. Ramos Mejia CPCRA CRS": "-34.608 -58.373", 
        "Hospital Italiano de Buenos Aires C601-020 CRS": "-34.608 -58.373", 
        "Hospital de Clinicas 'Jose de San Martin' C601-040 CRS": "-34.608 -58.373"
    }
}